Drugs / ECP-1014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04930354 | May → Sep 2023 | cancer | Euclises Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECP-1014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04930354 ↗ |
| Route | Oral | “ECP1014 oral capsule of10mg, 20mg, 40mg, 80mg and 160mg given once daily for 28 days” NCT04930354 ↗ |